Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
Illustration of blue and purple Nipah virus particles against a dark background.
The virus, initially isolated in Malaysia in 1998, has since caused outbreaks linked to contact with infected animals, particularly fruit bats of the Pteropus genus, or consumption of contaminated food products like raw date palm sap.
iStock, nopparit

Nipah Virus: Epidemiology, Pathogenesis, Treatment, and Prevention

A new review underscores the need for a multidisciplinary approach to address the threat of Nipah virus, including its high fatality rates in humans

Higher Education Press

Higher Education Press (HEP) is a publisher in China of university and college-level textbooks, owned by Ministry of Education of the People's Republic of China.

ViewFull Profile
Learn about ourEditorial Policies.
Published:Jan 17, 2025
|2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Fig 1. Nipah virus infection in humans.

Figure 1.

Limei Wang, Denghui Lu, Maosen Yang, Shiqi Chai, Hong Du, Hong Jiang

Nipah virus (NiV), a zoonotic paramyxovirus with significant human health implications, has garnered considerable attention due to its high fatality rates and potential for human-to-human transmission, posing a global public health threat.

Emerging in South and Southeast Asia, NiV is known for its recurrent outbreaks, with a particular focus on its genetic lineages, NiV-MY and NiV-BD, which differ in pathogenicity and transmissibility.

The virus, initially isolated in Malaysia in 1998, has since caused outbreaks linked to contact with infected animals, particularly fruit bats of the Pteropus genus, or consumption of contaminated food products like raw date palm sap.

Human infections of Nipah virus

Epidemiological insights reveal that NiV has demonstrated its ability to infect a wide range of hosts, from natural reservoirs like bats to domestic animals such as pigs, which act as intermediate hosts, facilitating transmission to humans.

Human infections have been reported across Malaysia, Singapore, Bangladesh, India, and the Philippines, with the virus exhibiting a propensity for causing severe disease and death.

Read More: Nipah Virus Outbreak in India: Should the US and Canada Be Concerned?

Nipah virus pathogenesis and symptoms

The pathogenesis of NiV involves initial infection in the respiratory tract, followed by systemic spread, leading to vasculitis and organ infection. The virus's ability to evade the host's immune response and cause endothelial cell damage contributes to its high pathogenicity.

Clinically, NiV presents with a range of symptoms, from nonspecific flu-like illness to severe neurological complications, with a significant risk of relapse and late-onset encephalitis in survivors.

Nipah virus treatment

Currently, there is no specific antiviral treatment for NiV infection, and management relies on supportive care. Ribavirin has been used empirically, but its efficacy remains uncertain due to conflicting results from in vitro studies and animal models.

The development of vaccines against NiV is a priority, with various approaches under investigation, including virus-like particle-based and mRNA-based vaccines. However, no vaccine is yet approved for human use.

Preventing spread of Nipah virus

Prevention strategies for NiV focus on reducing exposure to the virus through public health measures such as surveillance, education, and changes in agricultural practices. These include preventing access of bats to date palm sap and implementing strict hygiene measures in pig farming to curb virus transmission.

The review underscores the need for a multidisciplinary approach to address the NiV threat, including the development of effective therapeutics and vaccines, and the implementation of robust infection control measures to prevent outbreaks and protect public health.